Stockscreener 앱 받기
0.4728
13.00%
-0.0272
전일 마감가:
$0.50
열려 있는:
$0.42
하루 거래량:
1.47M
Relative Volume:
0.28
시가총액:
$1.95M
수익:
-
순이익/손실:
$-11.91M
주가수익비율:
-0.0533
EPS:
-8.8661
순현금흐름:
$-10.83M
1주 성능:
+61.71%
1개월 성능:
-44.44%
6개월 성능:
-84.95%
1년 성능:
-97.21%
1일 변동 폭
$0.4015
$0.4758
1주일 범위
$0.3658
$0.666
52주 변동 폭
$0.231
$22.36
Silexion Therapeutics Corp Stock (SLXN) Company Profile
명칭
Silexion Therapeutics Corp
전화
972-8-6286005
주소
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
0.4657 | 2.09M | 0 | -11.91M | -10.83M | -8.8661 |
VRTX
Vertex Pharmaceuticals Inc
|
435.62 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
640.47 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
800.86 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.89 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.09 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Silexion Therapeutics Corp 주식(SLXN)의 최신 뉴스
Silexion announces 1-for-10 reverse stock split effective Thursday - Investing.com
Silexion (NASDAQ: SLXN) plans 1-for-10 reverse share split to aid Nasdaq compliance - Stock Titan
Silexion Therapeutics Announces 1-for-10 Reverse Share Split - Yahoo Finance
Silexion Therapeutics (SLXN) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Stock ReactionAI Expert Picks - Newser
Silexion Therapeutics (SLXN): Modest Gains as Stock Holds Key Support at $0.46Percent Above MA - Newser
Silexion Therapeutics prices new warrants exercise deal at $0.50 to raise $1M - MSN
Silexion Therapeutics Stock Surges 97% on Phase 2/3 Trial Approval - Meyka
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN - TechStock²
Silexion Therapeutics(SLXN) Stock Options Chain | Quotes & News - Moomoo
Biotech Stock Silexion Therapeutics Corp. (NASDAQ: SLXN) Soars on Update and First Quarter Results - Investorideas.com
Silexion Therapeutics (SLXN) spikes as investors react to mid-May clinical-trial milestones and fresh financing - Quiver Quantitative
Silexion’s Cancer Trial Push Puts Focus on Cash - TechStock²
Silexion Therapeutics Posts Wider Q1 Loss, Advances SIL204 Into Phase 2/3 Trials; Stock Up - RTTNews
Silexion Therapeutics (SLXN) Gained +56.13% — Can It Break $0.44? 2026-05-20MAMA Signal - Newser
Silexion (NASDAQ: SLXN) 10-K amendment corrects internal control date - Stock Titan
Silexion Therapeutics (SLXN) Q1 2026 Earnings Surprise: EPS $-0.85, Up SignificantEPS Surprise History - Newser
Silexion Therapeutics 1Q Research and Development Approximately $1.4M >SLXN - Moomoo
Silexion Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update - Sahm
Silexion Therapeutics (SLXN) Declines -5.54% Amid Market Weakness 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Therapeutics (SLXN) Stock: Down -5.54%, Support Test at $0.26 2026-05-18{涓偂鍓爣棰榼 - Newser
Silexion Shares Decline After Update on German Regulatory Review - MSN
Silexion reports Q1 results, advances SIL204 clinical path - grafa.com
Silexion Therapeutics Reports Q1 2026 Financial Results and Submits Phase 2/3 Clinical Trial Application for Pancreatic Cancer in Germany - Minichart
Silexion Therapeutics reports Q1 2026 net loss $2.7M, cash $2.4M; SIL204 Phase 2/3 approval - TradingView
Pancreatic cancer RNAi trial moves ahead as Silexion ramps up spending - Stock Titan
Silexion (NASDAQ: SLXN) Q1 loss widens as SIL204 moves into Phase 2/3 - Stock Titan
TradingKey - TradingKey
Silexion Therapeutics Announces Exercise of Warrants for $1 Million Gross Proceeds - Sahm
Silexion (SLXNW) Drops -22.58% — Key Support at $0.01 2026-05-15Earnings Miss Stocks - newser.com
Silexion Therapeutics Announces Warrant Inducement Financing Agreement - TipRanks
Silexion Therapeutics Corp 1Q 2026: Net loss $2.7M, EPS ($0.85) — 10-Q Summary - TradingView
Silexion Therapeutics (NASDAQ: SLXN) posts higher Q1 loss and flags going concern risk - Stock Titan
Silexion Therapeutics Corp Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Warrant deal gives Silexion (NASDAQ: SLXN) $1.0M cash and new overhang - Stock Titan
Lind Global files 13G/A: 212,500 warrants in Silexion (SLXN) - Stock Titan
Silexion raises $1M through warrant exercise at $0.50/share - Investing.com
Cancer biotech Silexion swaps warrant deal for $1M in new funding - Stock Titan
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings for SIL204 in KRAS-Driven Pancreatic Cancer - Sahm
Silexion Announces Positive Preclinical Data for SIL204 Therapy - TipRanks
Silexion reports preclinical data on SIL204 in pancreatic cancer By Investing.com - Investing.com India
Silexion (SLXN) reports immune-related SIL204 signal in KRAS pancreatic cancer - Stock Titan
SLXNSilexion Therapeutics Corp stock news, filings & ratings - Quantisnow
Silexion Therapeutics reports positive preliminary immunotherapy findings for SIL204 in KRAS-driven pancreatic cancer - marketscreener.com
Silexion reports preclinical data on SIL204 in pancreatic cancer - Investing.com
Silexion Therapeutics Reports Positive Preliminary Immunotherapy Findings For Sil204 In Kras-Driven Pancreatic Cancer - TradingView
Silexion Therapeutics Reports Positive Preclinical Results for SIL204 in KRAS-Mutated Pancreatic Cancer Study - Quiver Quantitative
Silexion Therapeutics Reports Positive Preliminary - GlobeNewswire
Silexion Therapeutics initiates GMP clinical batch manufacturing of SIL204 - TipRanks
Silexion starts GMP manufacturing of SIL204 and gets Phase 2/3 trial approval for pancreatic cancer. - Pluang
Silexion Therapeutics Announces GMP Clinical Supply Manufacturing Initiation for SIL204 and New Approval – SEC 8-K Filing May 2026 - Minichart
Silexion Advances SIL204 With Manufacturing and Trial Approval - TipRanks
Silexion Therapeutics Corp (SLXN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.25%
0.46%
자본화:
|
볼륨(24시간):